Reference health
Mining the Epigenetic Landscape of Tissue Polarity in Search of New Targets for Cancer Therapy
100/100 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 100 checked references that resolve
resolves10.1007/s10911-010-9168-y
Tissue Polarity-Dependent Control of Mammary Epithelial Homeostasis and Cancer Development: an Epigenetic Perspective
resolves10.1038/nrc3130
A decade of exploring the cancer epigenome — biological and translational implications
resolves10.1038/nrc3486
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
resolves10.1016/j.yexcr.2004.04.024
DNA methylation control of tissue polarity and cellular differentiation in the mammary epithelium
resolves10.1091/mbc.e06-06-0551
NuMA Influences Higher Order Chromatin Organization in Human Mammary Epithelium
resolves10.1016/j.pharmthera.2013.02.004
Polarity proteins as regulators of cell junction complexes: Implications for breast cancer
resolves10.1242/jcs.03439
The control of tissue architecture over nuclear organization is crucial for epithelial cell fate
resolves10.1016/j.cell.2008.09.045
Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma
resolves10.1146/annurev-cellbio-092910-154244
Cell Polarity as a Regulator of Cancer Cell Behavior Plasticity
resolves10.1128/MCB.26.6.2387-2398.2006
Regulation of PCNA and Cyclin D1 Expression and Epithelial Morphogenesis by the ZO-1-Regulated Transcription Factor ZONAB/DbpA
resolves10.1073/pnas.97.13.7284
huASH1 protein, a putative transcription factor encoded by a human homologue of the
<i>Drosophila ash1</i>
gene, localizes to both nuclei and cell–cell tight junctions
resolves10.1128/MCB.00993-07
Mammalian ASH1L Is a Histone Methyltransferase That Occupies the Transcribed Region of Active Genes
resolves10.1158/0008-5472.CAN-07-6567
The Polarity Protein Par6 Induces Cell Proliferation and Is Overexpressed in Breast Cancer
resolves10.1128/MCB.00162-07
Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells
resolves10.1007/978-1-4419-9967-2_8
APC and DNA Demethylation in Cell Fate Specification and Intestinal Cancer
resolves10.1016/S1535-6108(02)00125-3
β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium
resolves10.1074/jbc.M606317200
Integrin β4 Regulates Migratory Behavior of Keratinocytes by Determining Laminin-332 Organization
resolves10.1016/0925-4773(96)00597-7
Nuclear localization of β-catenin by interaction with transcription factor LEF-1
resolves10.1242/jcs.049148
Regulation of β4-integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition
resolves10.1038/nsmb.2084
Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition
resolves10.1074/jbc.M803997200
Integrin α6β4 Controls the Expression of Genes Associated with Cell Motility, Invasion, and Metastasis, Including S100A4/Metastasin
resolves10.1016/j.bbrc.2015.02.012
Reversibility of the Snail-induced epithelial–mesenchymal transition revealed by the Cre–loxP system
resolves10.1074/jbc.M603767200
Crucial Roles of Sp1 and Epigenetic Modifications in the Regulation of the CLDN4 Promoter in Ovarian Cancer Cells
resolves10.1016/j.bbrc.2013.04.074
Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression
resolves10.1158/1078-0432.CCR-10-1461
Hypoexpression and Epigenetic Regulation of Candidate Tumor Suppressor Gene <i>CADM-2</i> in Human Prostate Cancer
resolves10.2119/molmed.2012.00243
Dapper Homolog 1 Is a Novel Tumor Suppressor in Gastric Cancer through Inhibiting the Nuclear Factor-κB Signaling Pathway
resolves10.1073/pnas.1108411109
Brush border Myosin Ia has tumor suppressor activity in the intestine
resolves10.3233/CBM-2012-0264
MPP3 inactivation by promoter CpG islands hypermethylation in colorectal carcinogenesis
resolves10.1074/jbc.M114.636126
DNA Methylation Affects the SP1-regulated Transcription of FOXF2 in Breast Cancer Cells
resolves10.1038/onc.2011.383
Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis
resolves10.1073/pnas.1004060107
The apical-basal cell polarity determinant Crumbs regulates Hippo signaling in
<i>Drosophila</i>
resolves10.4161/cc.9.16.12633
Lgl, the SWH pathway and tumorigenesis: It’s a matter of context and competition!
resolves10.1073/pnas.1004279107
The apical transmembrane protein Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to Expanded
resolves10.1016/j.cub.2010.03.019
Crumbs Regulates Salvador/Warts/Hippo Signaling in Drosophila via the FERM-Domain Protein Expanded
resolves10.1073/pnas.1315508111
Crumbs promotes expanded recognition and degradation by the SCF
<sup>Slimb/β-TrCP</sup>
ubiquitin ligase
resolves10.3389/fcell.2014.00005
HMGA proteins as modulators of chromatin structure during transcriptional activation
resolves10.1128/MCB.01304-10
Genomic DNA Hypomethylation by Histone Deacetylase Inhibition Implicates DNMT1 Nuclear Dynamics
resolves10.1038/sj.onc.1210776
Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells
resolves10.1016/j.biochi.2012.07.025
DNA methylation inhibitors in cancer: Recent and future approaches
resolves10.1016/j.drudis.2014.12.007
Discovery and development of DNA methyltransferase inhibitors using in silico approaches
resolves10.1200/JCO.2002.04.044
Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study
resolves10.1002/em.20363
Modulation of gene methylation by genistein or lycopene in breast cancer cells
resolves10.2217/epi.11.103
DNA Methylation and Soy Phytoestrogens: Quantitative Study in DU-145 and PC-3 Human Prostate Cancer Cell Lines
resolves10.1158/1078-0432.CCR-07-1320
A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia
resolves10.1158/1078-0432.CCR-08-2859
Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors
resolves10.1158/1078-0432.CCR-08-0122
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
resolves10.1007/s10637-008-9131-6
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
resolves10.1007/s13148-010-0012-4
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
resolves10.1007/s10637-015-0261-3
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
resolves10.1158/1078-0432.CCR-14-2556
<i>CCR</i> 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy
resolves10.3390/molecules20033898
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
resolves10.1158/1078-0432.CCR-06-0511
A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
resolves10.1038/nrclinonc.2013.42
The future of epigenetic therapy in solid tumours—lessons from the past
resolves10.2217/fon.11.2
Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer
resolves10.1016/j.ijrobp.2013.02.012
Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival
resolves10.1007/s11060-014-1433-2
Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial
resolves10.2217/epi.12.68
Demethylation and Re-Expression of Epigenetically Silenced Tumor Suppressor Genes: Sensitization of Cancer Cells by Combination Therapy
resolves10.1186/1476-4598-6-10
Identification of candidate methylation-responsive genes in ovarian cancer
resolves10.1038/nchembio.1084
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
resolves10.1038/nature11606
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
resolves10.1038/nchembio.599
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
resolves10.1021/cb300139y
A Small-Molecule Probe of the Histone Methyltransferase G9a Induces Cellular Senescence in Pancreatic Adenocarcinoma
resolves10.1016/j.ccr.2011.06.009
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
resolves10.1038/nchembio721
Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9
resolves10.1002/cmdc.201300428
A Cell‐Permeable Ester Derivative of the JmjC Histone Demethylase Inhibitor IOX1
resolves10.1038/nm.2100
An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB
resolves10.1016/j.canlet.2014.11.003
EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma
resolves10.1093/emboj/cdg542
EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer
resolves10.1158/0008-5472.CAN-05-4300
Identification of EZH2 as a Molecular Marker for a Precancerous State in Morphologically Normal Breast Tissues
resolves10.2353/ajpath.2009.090042
Targeted Overexpression of EZH2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia
resolves10.3892/mmr.2015.3378
Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer
resolves10.18632/oncotarget.3077
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
resolves10.1073/pnas.1308953111
EZH2 expands breast stem cells through activation of NOTCH1 signaling
resolves10.1371/journal.pgen.1002517
The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer
resolves10.1093/nar/gku937
CTCF induces histone variant incorporation, erases the H3K27me3 histone mark and opens chromatin
resolves10.1128/MCB.00567-14
CTCF Controls <i>HOXA</i> Cluster Silencing and Mediates PRC2-Repressive Higher-Order Chromatin Structure in NT2/D1 Cells
resolves10.1371/journal.pone.0067496
Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4
The 3 references without a DOI — listed, not checked
no DOI — not checkedByler S , GoldgarS , HeerbothSet al. Genetic and epigenetic aspects of breast cancer progression and therapy . Anticancer Res.34 ( 3 ), 1071 – 1077 ( 2014 ).
no DOI — not checkedSarkar S , AbujamraAL , LoewJE , FormanLW , PerrineSP , FallerDV . Histone deacetylase inhibitors reverse cpg methylation by regulating dnmt1 through erk signaling . Anticancer Res.31 ( 9 ), 2723 – 2732 ( 2011 ).
no DOI — not checkedBoumber Y , IssaJP . Epigenetics in cancer: what’s the future?Oncology (Williston Park)25 ( 3 ), 220 – 226 , 228 ( 2011 ).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2217/epi.15.83"><img src="https://citestamp.com/citestamped/10.2217/epi.15.83/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2217/epi.15.83)